CD274 and non-small cell lung carcinoma: In addition, lipid metabolism status has the potential to function as a prognostic indicator for determining the eligibility of patients with advanced NSCLC, who may gain advantages from the combination of anlotinib and PD-1/PD-L1 inhibitors.